US EditionDialectic Therapeutics Announces Dosing of First Patient in Platinum-Resistant Ovarian Cancer (PROC)
DT2216 targets BCL-XL protein and showed strong preclinical tumor regressions; first two patients dosed in trial led by Dana-Farber Cancer Institute.
- On Nov. 19, 2025, Dialectic Therapeutics, Inc. announced Dr. Elizabeth Stover, IND-holder, recruited the first two patients as dosing began; trial info is available via 877 or Joshua Sills.
- Because DT2216 selectively degrades BCL-XL, preclinical studies using PDX models including DF83 and OVCAR3 showed rapid tumor regressions and complete eradication, supporting clinical testing.
- The company's Phase 1a trial ran across six dose-escalating cohorts and established an RP2D with favorable safety, while biomarkers showed DT2216 degraded the BCL-XL target protein in all patients in that cohort.
- Investigators emphasize urgent patient need and trial initiation, noting new options are critical for patients with platinum‑resistant ovarian cancer, while Dr. Ursula Matulonis called the preclinical data compelling and CPRIT supports ongoing development.
- Collaborations with Harvard School of Public Health and Dana‑Farber Cancer Institute demonstrate DT2216’s translational potential in chemo-resistant models, and if clinical efficacy mirrors preclinical data, it could offer new treatment options.
12 Articles
12 Articles
Dialectic Therapeutics Announces Dosing of First Patient in Platinum-Resistant Ovarian Cancer (PROC)
DALLAS, Nov. 19, 2025 /PRNewswire/ -- Dialectic Therapeutics, Inc., a clinical-stage biotechnology company developing innovative anti-cancer drugs, today announced that patient dosing is underway in a clinical trial led by the renowned Drs. Elizabeth Stover, Joyce Liu, and Ursula Matulonis…
Dialectic Therapeutics Announces Dosing of First Patient in Platinum-Resistant Ovarian Cancer (PROC)
DALLAS, Nov. 19, 2025 /PRNewswire/ -- Dialectic Therapeutics, Inc., a clinical-stage biotechnology company developing innovative anti-cancer drugs, today announced that patient dosing is underway in a clinical trial led by the renowned Drs. Elizabeth Stover, Joyce Liu, and Ursula Matulonis…
Dialectic Therapeutics Announces Dosing of First Patient in Platinum-Resistant Ovarian Cancer (PROC)
DALLAS, Nov. 19, 2025 /PRNewswire/ -- Dialectic Therapeutics, Inc., a clinical-stage biotechnology company developing innovative anti-cancer drugs, today announced that patient dosing is underway in a clinical trial led by the renowned Drs. Elizabeth Stover, Joyce Liu, and Ursula Matulonis…
Dialectic Therapeutics Announces Dosing of First Patient in Platinum-Resistant Ovarian Cancer (PROC)
DALLAS, Nov. 19, 2025 /PRNewswire/ -- Dialectic Therapeutics, Inc., a clinical-stage biotechnology company developing innovative anti-cancer drugs, today announced that patient dosing is underway in a clinical trial led by the renowned Drs. Elizabeth Stover, Joyce Liu, and Ursula Matulonis…
Dialectic Therapeutics Announces Dosing of First Patient in Platinum-Resistant Ovarian Cancer (PROC)
Dialectic Therapeutics, Inc., a clinical-stage biotechnology company developing innovative anti-cancer drugs, today announced that patient dosing is underway in a clinical trial led by the renowned Drs. Elizabeth Stover, Joyce Liu, and Ursula Matulonis from the Dana-Farber Cancer Institute.
Dialectic Therapeutics Announces Dosing of First Patient in Platinum-Resistant Ovarian Cancer (PROC)
DALLAS, Nov. 19, 2025 /PRNewswire/ -- Dialectic Therapeutics, Inc., a clinical-stage biotechnology company developing innovative anti-cancer drugs, today announced that patient dosing is underway in a clinical trial led by the renowned Drs. Elizabeth Stover, Joyce Liu, and Ursula Matulonis…
Coverage Details
Bias Distribution
- 75% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
